- Home
- FENG vs CGTX Comparison
FENG vs CGTX Comparison
Compare FENG & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENG
- CGTX
- Stock Information
- Founded
- FENG 1998
- CGTX 2007
- Country
- FENG China
- CGTX United States
- Employees
- FENG N/A
- CGTX N/A
- Industry
- FENG Broadcasting
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- FENG Industrials
- CGTX Health Care
- Exchange
- FENG Nasdaq
- CGTX Nasdaq
- Market Cap
- FENG 25.2M
- CGTX 25.1M
- IPO Year
- FENG 2011
- CGTX 2021
- Fundamental
- Price
- FENG $2.27
- CGTX $0.61
- Analyst Decision
- FENG
- CGTX Strong Buy
- Analyst Count
- FENG 0
- CGTX 4
- Target Price
- FENG N/A
- CGTX $2.83
- AVG Volume (30 Days)
- FENG 7.7K
- CGTX 17.3M
- Earning Date
- FENG 08-12-2025
- CGTX 08-07-2025
- Dividend Yield
- FENG N/A
- CGTX N/A
- EPS Growth
- FENG N/A
- CGTX N/A
- EPS
- FENG N/A
- CGTX N/A
- Revenue
- FENG $97,280,369.00
- CGTX N/A
- Revenue This Year
- FENG N/A
- CGTX N/A
- Revenue Next Year
- FENG N/A
- CGTX N/A
- P/E Ratio
- FENG N/A
- CGTX N/A
- Revenue Growth
- FENG 1.04
- CGTX N/A
- 52 Week Low
- FENG $1.28
- CGTX $0.22
- 52 Week High
- FENG $4.14
- CGTX $2.54
- Technical
- Relative Strength Index (RSI)
- FENG 56.10
- CGTX 65.40
- Support Level
- FENG $2.17
- CGTX $0.56
- Resistance Level
- FENG $2.39
- CGTX $1.04
- Average True Range (ATR)
- FENG 0.15
- CGTX 0.09
- MACD
- FENG 0.01
- CGTX 0.03
- Stochastic Oscillator
- FENG 67.55
- CGTX 43.43
About FENG Phoenix New Media Limited
Phoenix New Media Ltd is a media company providing premium content on an integrated platform across the internet, mobile and TV channels in China. The company organizes its operations into two main segments: Net advertising services and Paid services. It provides its content and services through three channels: ifeng.com channel, video channel, and mobile channel. The company also offers a wide range of paid services including mobile value-added services, games, and content sales. It generates the majority of its revenue from Net advertising services. Geographically, it derives revenue from China.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.